To include your compound in the COVID-19 Resource Center, submit it here.

A chromatin target for ALL

A New York University School of Medicine-GlaxoSmithKline plc collaboration has shown that an inhibitor of the chromatin regulator JMJD3 could help treat T cell acute lymphoblastic leukemia.1 As JMJD3 is upregulated and used as a notch partner in T cell leukemia specifically, and not during T cell development, the researchers hope that targeting the epigenetic modulator could avoid the safety pitfalls of general notch pathway suppression.

Current treatments for T cell acute lymphoblastic leukemia (T-ALL) involve combination chemotherapy regimens that have considerable toxic side effects. Apart from drugs that inhibit BCR-ABL tyrosine kinase fusion proteins, no targeted therapies are marketed for the disease.

The notch pathway is particularly attractive for drug development because it is overactivated in the majority of T-ALLs. However,

Read the full 1204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers